Targeted therapeutic options for gastric adenocarcinoma mainly include trastuzumab, apatinib and ramorubicin, etc. These targeted therapeutic options are mainly used in the treatment of advanced gastric adenocarcinoma. 1. Trastuzumab is mainly used for the first-line treatment of advanced gastric adenocarcinoma patients with high expression of Her2 gene. This targeted drug is usually used in combination with systemic chemotherapy, and effective treatment can prolong the survival time of patients for more than one year. 2. Apatinib is a small molecule oral anti-angiogenic targeted drug, currently approved for the third-line treatment of advanced gastric adenocarcinoma patients, studies have confirmed that compared with placebo, Apatinib can prolong the survival time of patients. 3. Remodulizumab is a monoclonal antibody drug, targeting vascular endothelial growth factor receptor 2 (VEGFR2), preventing the proliferation and migration of vascular endothelium by inhibiting ligand-stimulated VEGFR2 activation, combined with chemotherapeutic drugs, it can be used for the treatment of gastric cancer.